Pursuant to Regulation 30 and Regulation 33 of SEBI (LODR) Regulations, 2015 this is to inform you that the Board of Directors at its meeting held on Thursday, 12th February, 2026 has inter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences reported a massive jump in revenues for Q3 FY26, with standalone revenue from operations at ₹4,493.26 lakhs compared to just ₹76.21 lakhs in Q3 FY25. For the nine-month period, standalone revenue surged to ₹10,648.51 lakhs versus ₹276.47 lakhs in 9M FY25. Standalone profit after tax for Q3 was ₹16.05 lakhs (up from ₹3.78 lakhs) and ₹64.12 lakhs for nine months (up from ₹28.08 lakhs). On a consolidated basis, including subsidiary Vivanza Life Sciences, 9M revenue reached ₹10,954.77 lakhs and PAT was ₹84.52 lakhs (vs ₹32.40 lakhs). The statutory auditor issued an unqualified limited review report with no qualifications, emphasis of matter, or observations. The company operates across Agro, pharmaceuticals, and Films segments. Worth noting: full-year FY25 had a consolidated loss of ₹67.41 lakhs, but profitability has returned in the current periods.
The explosive top-line growth suggests a major scaling of business operations, but profitability remains razor-thin (PBT margin of around 0.36% on standalone basis in Q3). For shareholders, the story is one of rapid revenue expansion with weak margins — sustained growth and margin improvement will be key things to watch in coming quarters.